Phillip Pang - Nov 17, 2021 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Medical Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Nov 17, 2021
Transactions value $
-$153,380
Form type
4
Date filed
11/19/2021, 03:51 PM
Previous filing
Nov 4, 2021
Next filing
Dec 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $25.9K +5K +4.99% $5.18 105K Nov 17, 2021 Direct
transaction VIR Common Stock Sale -$162K -4.54K -4.31% $35.75 101K Nov 17, 2021 Direct F1, F2
transaction VIR Common Stock Sale -$17.1K -465 -0.46% $36.80 100K Nov 17, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -5K -10.61% $0.00 42.1K Nov 17, 2021 Common Stock 5K $5.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.21 to $35.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.